Business Description
OncoZenge AB
ISIN : SE0015504097
Share Class Description:
OSTO:ONCOZ: Ordinary SharesCompare
Compare
Traded in other countries / regions
ONCOZ.Sweden8LY.Germany IPO Date
2021-02-12Description
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.92 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -131.1 | |||||
| 3-Year EPS without NRI Growth Rate | -150 | |||||
| 3-Year Book Growth Rate | -26.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 30.64 | |||||
| 9-Day RSI | 39.81 | |||||
| 14-Day RSI | 43.96 | |||||
| 6-1 Month Momentum % | 45.19 | |||||
| 12-1 Month Momentum % | -40.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 7.94 | |||||
| Quick Ratio | 7.94 | |||||
| Cash Ratio | 7.43 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -61.68 | |||||
| ROA % | -56.67 | |||||
| ROIC % | -189.33 | |||||
| ROCE % | -61.68 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.34 | |||||
| Price-to-Tangible-Book | 3.67 | |||||
| EV-to-EBIT | -1.46 | |||||
| EV-to-Forward-EBIT | -3.01 | |||||
| EV-to-EBITDA | -1.46 | |||||
| EV-to-Forward-EBITDA | -3.01 | |||||
| EV-to-Forward-Revenue | 0.41 | |||||
| EV-to-FCF | -1.53 | |||||
| Price-to-Net-Current-Asset-Value | 3.67 | |||||
| Price-to-Net-Cash | 3.99 | |||||
| Earnings Yield (Greenblatt) % | -68.52 | |||||
| FCF Yield % | -39.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OncoZenge AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -1.361 | ||
| Beta | 0 | ||
| Volatility % | 92.85 | ||
| 14-Day RSI | 43.96 | ||
| 14-Day ATR (kr) | 0.336566 | ||
| 20-Day SMA (kr) | 3.95 | ||
| 12-1 Month Momentum % | -40.83 | ||
| 52-Week Range (kr) | 1.6 - 8.5 | ||
| Shares Outstanding (Mil) | 11.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OncoZenge AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OncoZenge AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
OncoZenge AB Frequently Asked Questions
What is OncoZenge AB(OSTO:ONCOZ)'s stock price today?
The current price of OSTO:ONCOZ is kr3.71. The 52 week high of OSTO:ONCOZ is kr8.50 and 52 week low is kr1.60.
When is next earnings date of OncoZenge AB(OSTO:ONCOZ)?
The next earnings date of OncoZenge AB(OSTO:ONCOZ) is 2024-05-21.
Does OncoZenge AB(OSTO:ONCOZ) pay dividends? If so, how much?
OncoZenge AB(OSTO:ONCOZ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers